Alport Syndrome research hub

BAY3401016; Biomarker Study Alport

This study is looking into a new medication called BAY 3401016 for adults with Alport Syndrome, a genetic kidney condition. It aims to see if this medicine can help slow down kidney damage by blocking a specific protein.

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

This study is looking at a new medicine called sparsentan for children aged 1 to 17 with certain kidney conditions like FSGS, MCD, IgAN, IgAV, and Alport Syndrome. It will check if the medicine is safe, works well, and how the body handles it over two years.

National Registry of Rare Kidney Diseases

This registry is collecting information from people with rare kidney diseases across the UK. It aims to improve understanding, create better care guidelines, and help develop new treatments for these conditions. If you have a rare kidney disease, your information could help.

Atrasentan in Patients With Proteinuric Glomerular Diseases

This study looks at a new medicine called atrasentan for people with certain kidney diseases. It aims to see if atrasentan can help reduce protein in the urine and protect kidney function. Different groups of patients with kidney conditions like IgA nephropathy and diabetic kidney disease are being included.

A study to learn how safe the study treatment BAY3401016 is, how it affects the body and how it moves into, through, and out of the body when a single amount is given to healthy male participants

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the NOX1/4 Inhibitor Setanaxib in Patients with Alport Syndrome

Vonafexor fixed dose-escalation safety and proof-of-concept study in patients with at risk of progression Alport syndrome